SCHEMBL968877

SCHEMBL968877

COc1cc2c3c([nH]c2cn1)CN(CC(=O)N1CCN(C2CCC2)CC1)CC3

nearest known ligand 0.47

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
PARP1 P09874 3/20 0.47
ALDH1A1 P00352 6/20 0.39
KDM4E B2RXH2 1/20 0.39
HPGD P15428 1/20 0.39
NPC1 O15118 1/20 0.39
HRH3 Q9Y5N1 4/20 0.38
KMT2A Q03164 3/20 0.38
TSHR P16473 1/20 0.38
HDAC1 Q13547 2/20 0.38
HDAC6 Q9UBN7 2/20 0.38
MEN1 O00255 2/20 0.37
GAA P10253 2/20 0.36
MAPT P10636 2/20 0.36
CNR2 P34972 1/20 0.36
USP2 O75604 1/20 0.36
CASP1 P29466 1/20 0.36
CASP7 P55210 1/20 0.36
GLA P06280 1/20 0.36
CNR1 P21554 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13985932 0.86 PARP1 (0.49) PARP1ALDH1A1KDM4EHPGDNPC1
SCHEMBL968745 0.85 PARP1 (0.47) PARP1ALDH1A1KDM4EHPGDNPC1
SCHEMBL967938 0.84 HDAC1 (0.54) PARP1ALDH1A1KDM4EHPGDNPC1
SCHEMBL969771 0.83 PARP1 (0.52) PARP1ALDH1A1KDM4EHPGDNPC1
SCHEMBL967791 0.83 NPC1 (0.58) PARP1ALDH1A1KDM4EHPGDNPC1
SCHEMBL967354 0.82 PARP1 (0.47) PARP1ALDH1A1KDM4EHRH3KMT2A
SCHEMBL969816 0.82 PARP1 (0.39) PARP1ALDH1A1KDM4ENPC1HRH3
SCHEMBL967154 0.81 PARP1 (0.52) PARP1ALDH1A1KDM4EHPGDHRH3
SCHEMBL966792 0.81 PARP1 (0.47) PARP1ALDH1A1KDM4EHPGDHRH3
SCHEMBL969260 0.79 PARP1 (0.52) PARP1ALDH1A1KDM4EHPGDNPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20110002855-A1 PIPERAZINYL OXOALKYL TETRAHYDRO-BETA-CARBOLINES AND RELATED ANALOGUES NEUROGEN CORPORATION (US) 2011-01-06 US disclosed
US-20110002855-A1 PIPERAZINYL OXOALKYL TETRAHYDRO-BETA-CARBOLINES AND RELATED ANALOGUES NEUROGEN CORPORATION (US) 2011-01-06 US disclosed
US-20110002855-A1 PIPERAZINYL OXOALKYL TETRAHYDRO-BETA-CARBOLINES AND RELATED ANALOGUES NEUROGEN CORPORATION (US) 2011-01-06 US disclosed
WO-2009003003-A2 PIPERAZINYL OXOALKYL TETRAHYDRO-BETA-CARBOLINES AND RELATED ANALOGUES NEUROGEN CORPORATION (US) 2008-12-31 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110002855-A1 PIPERAZINYL OXOALKYL TETRAHYDRO-BETA-CARBOLINES AND RELATED ANALOGUES HRH3, HRH4, HRH1 PARP1 2898/4885ALDH1A1 812/4885KDM4E 3037/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.